Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113790 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Ali Salimi Asl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Electronic address: shervin7717@gmail.…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Immunotherapy, Skin Neoplasms, Papillomavirus Infections. Die Arbeit nennt 166 Literaturangaben.
Abstract (Originalsprache)
Skin cancer is the most common new cancer among Caucasians. This cancer has different types, of which non-melanoma skin cancer is the most common type. Various factors affect this disease, one of which is viral infections, including HPV. This virus plays an important role in skin cancer, especially cSCCs. There are various options for the treatment of skin cancer, and today special attention has been paid to treatments based on therapeutic goals, immunotherapy and combination therapy. In this study, we have investigated treatments based on immunotherapy and virotherapy and the effect of HPV virus on the effectiveness of these treatments in skin cancer. Treatments based on virotherapy are performed for a long time in combination with other common treatments such as radiotherapy and chemotherapy in order to have a greater effect and lower its side effects, which include: shortness of breath, tachycardia, lowering blood pressure in the patient. Also, the most important axis of immunotherapy is to focus on PD1-PDL1, despite abundant evidence on the importance of immunotherapy, many studies investigate the use of immunotherapy inhibitors in the adjuvant and neoadjuvant setting in various cancers. Also, previous findings show conflicting evidence of the effect of HPV status on the response to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Electronic address: shervin7717@gmail.com.
- Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Electronic address: mohsendavari78@gmail.com.
- Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran; Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. Electronic address: atousaghorbani05@gmail.com.
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Narjes.seddighi80@gmail.…
- Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran. Electronic address: kimia.arabi95@gmail.com.
- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Genetics and Molecular Medicine Department, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Ele…
Zitieren
APA
Salimi Asl, A., Davari, M., Ghorbani, A., Seddighi, N., Arabi, K., & Saburi, E. (2025). Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113790
Vancouver
Salimi Asl A, Davari M, Ghorbani A, Seddighi N, Arabi K, Saburi E. Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113790
BibTeX
@article{SalimiAsl2025,
author = {Salimi Asl, Ali and Davari, Mohsen and Ghorbani, Atousa and Seddighi, Narjes and Arabi, Kimia and Saburi, Ehsan},
title = {Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113790}
}
EUVIMED